AI assistant
Moderna, Inc. — Director's Dealing 2020
Sep 1, 2020
30610_dirs_2020-09-01_5b158018-1021-42b9-9596-cbabe41e197b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-08-31
Reporting Person: Zaks Tal Zvi (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-08-31 | Common Stock | M | 10000 | $20.93 | Acquired | 10000 | Direct |
| 2020-08-31 | Common Stock | M | 5000 | $12.21 | Acquired | 15000 | Direct |
| 2020-08-31 | Common Stock | M | 5000 | $14.22 | Acquired | 20000 | Direct |
| 2020-08-31 | Common Stock | M | 10000 | $19.15 | Acquired | 30000 | Direct |
| 2020-08-31 | Common Stock | S | 8670 | $63.09 | Disposed | 21330 | Direct |
| 2020-08-31 | Common Stock | S | 14700 | $64.16 | Disposed | 6630 | Direct |
| 2020-08-31 | Common Stock | S | 4807 | $64.81 | Disposed | 1823 | Direct |
| 2020-08-31 | Common Stock | S | 1823 | $66.52 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-08-31 | Stock Option (Right to Buy) | $20.93 | M | 10000 | Disposed | 2029-03-08 | Common Stock (10000) | Direct |
| 2020-08-31 | Stock Option (Right to Buy) | $12.21 | M | 5000 | Disposed | 2027-02-23 | Common Stock (5000) | Direct |
| 2020-08-31 | Stock Option (Right to Buy) | $14.22 | M | 5000 | Disposed | 2028-02-28 | Common Stock (5000) | Direct |
| 2020-08-31 | Stock Option (Right to Buy) | $19.15 | M | 10000 | Disposed | 2026-08-10 | Common Stock (10000) | Direct |
Footnotes
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.56 to $63.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.57 to $64.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.58 to $65.55. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.19 to $67.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6: 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.
F7: 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.
F8: This option is fully vested and exercisable.